Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia.

@article{Wessells2003IncidenceAS,
  title={Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia.},
  author={Hunter Wessells and Johnny B. Roy and John Bannow and John T. Grayhack and Alvin M. Matsumoto and Lisa Tenover and Richard Herlihy and William Fitch and Richard F. Labasky and Stephen M. Auerbach and Ra{\'u}l Parra and Jacob Rajfer and Jennifer L Culbertson and Michael Bin Lee and Mark A Bach and Joanne Waldstreicher},
  journal={Urology},
  year={2003},
  volume={61 3},
  pages={
          579-84
        }
}
OBJECTIVES To evaluate the incidence and resolution of sexual adverse experiences (AEs) in men with benign prostatic hyperplasia treated with finasteride 5 mg compared with placebo. METHODS The Proscar Long-term Efficacy and Safety Study (PLESS) was a 4-year, randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of finasteride 5 mg in 3040 men, aged 45 to 78 years, with symptomatic benign prostatic hyperplasia, enlarged prostates, and no evidence of prostate… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 45 CITATIONS

Safety and Tolerability of Treatment for BPH

VIEW 4 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

Development of finasteride polymer microspheres for systemic application in androgenic alopecia

Ju Kim, Jungtae Na, +9 authors Hyun‑Shik Lee
  • International journal of molecular medicine
  • 2019
VIEW 1 EXCERPT
CITES BACKGROUND

Das Post-Finasterid-Syndrom

  • Gynäkologische Endokrinologie
  • 2017
VIEW 2 EXCERPTS
CITES BACKGROUND